

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
**WO 03/080157 A1**

(51) International Patent Classification<sup>7</sup>: **A61M 5/142,**  
5/172

(21) International Application Number: **PCT/BE03/00050**

(22) International Filing Date: 24 March 2003 (24.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0206792.4 22 March 2002 (22.03.2002) GB

(71) Applicant (for all designated States except US): **K. U. LEUVEN RESEARCH AND DEVELOPMENT** [BE/BE]; Groot Begijnhof, Benedenstraat 59, B-3000 Leuven (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VAN DEN BERGHE, Greta** [BE/BE]; Rue de Beaumont 77, B-1390 Grez-Doiceau (BE). **BERCKMANS, Daniel** [BE/BE]; Slangenstraat 37, B-3010 Kessel-Lo (BE). **AERTS, Jean-Marie** [BE/BE]; Konijnenhoekstraat 8, B-3053 Haasrode (BE). **DE MOOR, Bart** [BE/BE];

Parklaan 5, B-3360 Bierbeek (BE). **PLUYMERS, Bert** [BE/BE]; Drie Engelenstraat 20, B-2260 Westerlo (BE). **DE SMET, Frank** [BE/BE]; Mechelsveldstraat 50 bus 201, B-2800 Mechelen (BE).


(74) Common Representative: **K. U. LEUVEN RESEARCH AND DEVELOPMENT**; Ivo Roelants, IPR Officer, Groot Begijnhof, Benedenstraat 59, B-3000 Leuven (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: AUTOMATIC INFUSION SYSTEM BASED ON AN ADAPTIVE PATIENT MODEL



(57) Abstract: Present invention is a system of blood glucose monitoring and intensive insulin therapy in a ICU for strict maintenance of normoglycemia which reduces intensive care and hospital mortality and morbidity of critically ill adult patients. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established. The invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity). This automated insulin monitoring systems significantly reduces the workload and human resource management problems for intensive insulin therapy in patients in the ICU.

WO 03/080157 A1



**Declaration under Rule 4.17:**

*of inventorship (Rule 4.17(iv)) for US only*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

*with international search report*

*before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

## AUTOMATIC INFUSION SYSTEM BASED ON AN ADAPTIVE PATIENT MODEL

## FIELD OF THE INVENTION

5 This invention relates to algorithmic control of insulin titration and blood glucose monitoring for reducing intensive care and hospital mortality and morbidity (such as critical illness polyneuropathy, bacteremia, inflammation and anemia) of critically ill patients in an ICU, preferably a surgical ICU. More specifically present invention involves an algorithm and a system to reduce mortality and morbidity in critically ill  
10 patients (who require intensive care) through a software-assisted control of glycemia (concentration of glucose in the blood).

## TECHNICAL BACKGROUND

15 Hyperglycemia and insulin resistance are common in critically ill patients, even when glucose homeostasis has previously been normal. Increased gluconeogenesis, despite abundantly released insulin, is probably central to this disruption of glucoregulation (Wolfe RR, et al Metabolism 1979; 28: 210-220 Wolfe RR, et al. N Engl J Med. 1987; 317: 403-408).

20 Hence, the liver appears a major site of insulin resistance. Reduced insulin-stimulated glucose uptake also exists in skeletal muscle and heart (Wolfe RR, et al Metabolism 1979; 28: 210-220, Shangraw RE, et al. Metabolism 1989; 38: 983-9893). Overall glucose uptake, however, is increased but takes place mainly in insulin-independent tissues such as the brain, the red blood cells and in wounds.

25 The increased glucose turnover and insulin-resistance of hyperglycemia were previously interpreted as a plea for tolerating moderately elevated ( $\leq 215$  mg/dl) blood glucose levels during critical illness (Mizock BA. et al. Am J Med. 1995; 98:75-84; McCowen KC, et al. Crit Care Clin. 2001; 17: 107-124). More pronounced hyperglycemia in diabetic surgical patients has been associated with  
30 high incidence of postoperative infections (Fietsam R jr, et al. Am Surg. 1991; 57: 551-557) and after stroke and head injury with poor prognosis (O'Neill PA, Davies I,

Scott JF, et al. Stroke 1999). In diabetic patients suffering from acute myocardial infarction, blood glucose control below 215 mg/dl has been shown to improve long-term outcome (Malmberg K, et al. Circulation. 1999; 99: 2626-2632; Malmberg K BMJ 1997; 314: 1512-1515; Malmberg K, et al. J Am Coll Cardiol. 1995; 26: 57-  
5 65). We recently hypothesized that even moderate hyperglycemia, between 110 mg/dl and 200 mg/dl, in diabetic as well as in non-diabetic critically ill patients is directly or indirectly harmful to vital organs and systems (Van den Berghe G, et al. N Engl J Med. 2001; 345: 1359-1367) hence contributing to adverse outcome. A prospective, randomized, controlled study performed in 1548 ICU patients  
10 confirmed this hypothesis by showing that strict glycemic control below 110 mg/dl with insulin infusion substantially reduces morbidity and mortality (Van den Berghe G, et al. N Engl J Med. 2001; 345: 1359-1367). Indeed, intensive insulin therapy reduced overall ICU mortality from 8% to 4.6%, and from 20.2% to 10.6% among patients requiring more than 5 days intensive care. Intensive insulin therapy also  
15 halved the incidence of blood stream infections, prolonged inflammation, acute renal failure requiring dialysis or hemofiltration, critical illness polyneuropathy and transfusion requirements. Patients receiving intensive insulin therapy were also less likely to require prolonged mechanical ventilation and intensive care. It remained an open question, however, whether the benefits are brought about  
20 directly by the infused insulin per se or by the prevention of hyperglycemia, as both occurred concomitantly.

Present findings clearly demonstrate that strict maintenance of normoglycemia with intensive insulin therapy reduces intensive care and hospital mortality and morbidity  
25 of critically ill adult patients in a surgical ICU. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established.

30 By a prospective, randomized, controlled trial in a single center in a 56-bed predominantly surgical ICU in a tertiary teaching hospital 1548 patients were

randomly assigned to either strict normalization of blood glucose (80-110 mg/dl) with intensive insulin therapy from ICU admission onward or the conventional approach, in which insulin infusion is only initiated when blood glucose exceeds 215 mg/dL, to maintain blood glucose levels between 180 and 200 mg/dl. It was  
5 feasible and safe to achieve and maintain blood glucose levels below 110 mg/dL by using a simple insulin titration algorithm which takes on-admission patient- and disease-related factors such as BMI, history of diabetes, reason for ICU admission, severity of illness, on-admission hyperglycemia, as well as the caloric intake, time in ICU and concomitant medication (glucocorticoids) into account. Stepwise  
10 regression analysis indicated that, except for severity of illness and use of glucocorticoids, all these factors were independent determinants of mean insulin requirements, together explaining 36% of its variation. Nutritional intake was progressively increased from a mean 550 Cal on day 1 to a mean 1600 Cal from day 7 onward. The dose of insulin required to reach normoglycemia was highest  
15 and most variable during the first 6 hours after admission (a mean of 7 units per hour; 10% of the patients required more than 20 units per hour). Normoglycemia was reached within 24h with, for a 70 kg patient, a mean 77 units per day on the first day and 94 units per day on day 7. Between day 7 and 12, caloric intake remained stable but insulin requirements decreased by 40%. Brief and clinically  
20 harmless hypoglycemia occurred in 5.2% of intensive insulin treated patients on the median 6<sup>th</sup> (IQR 2<sup>nd</sup> -14<sup>th</sup>) day versus in 0.8% of the conventionally treated patients on the 11<sup>th</sup> (2<sup>nd</sup> - 10<sup>th</sup>) day.

The observed benefits of intensive insulin therapy on morbidity and mortality were equally present whether or not patients received enteral feeding. The lowered  
25 blood glucose level rather than the insulin dose was related to the observed reduction in mortality ( $P<0.0001$ ), critical illness polyneuropathy ( $P<0.0001$ ), bacteremia ( $P=0.02$ ) and inflammation ( $P=0.0006$ ) but not to the prevention of acute renal failure, for which the insulin dose was an independent determinant ( $P=0.03$ ). Among long-stay patients, maintaining strict normoglycemia appeared important for  
30 optimal risk reduction as intermediate (110-150 mg/dl) blood glucose levels were

associated with a significantly higher incidence of most intensive care complications and death.

It has now demonstrated by that glycemia between 80 and 110 mg/dl (4.4 and 5 6.1 mmol/l), through a rigorous administration of insulin (intensive insulin therapy) can result in a spectacular reduction in mortality and morbidity. This major step forward in the treatment of critically ill patients, particularly since most large clinical trials on immunomodulatory treatment of sepsis and shock failed to demonstrate benefit.

10

However, intensive monitoring with fast and easy access of blood glucose may be a useful in order to accurately steer the delivery of insulin or insulin releasing factors. Malberg K.A., et al. 1994 (Diabetes Care 17: 1007 – 1014 (1994)), for instance, demonstrated that in a study of glucose control following myocardial 15 infarction that infusion with insulin and glucose resulted in 18% of the patients developing hypoglycaemia. A hypoglycaemia defined as blood glucose below 0.3 mM/litre, is for instance known to increases risk of myocardial infarction and ventricular arrhythmia.

20 Moreover, Sakuri Y. et al. (Annals of surgery Vol. 222 No. 3 283 – 297 (1995)) demonstrated that burned patients have a negative balance between protein synthesis and breakdown, despite a nutritional intake and concluded that mechanism responsible for this imbalance was principally a high rate of protein breakdown. Sakuri Y. et al. Found that chronic insulin delivery 28 units/hour, 25 could increase the protein breakdown. Although this striking finding that insulin infusion increases protein breakdown, in healthy volunteers as well in burned patients insulin delivery ameliorated the net catabolism of muscle protein. Sakuri K.A. et al concluded that for treatment of burned patient by insulin a lower dose would be preferable because of the potential problems of giving a caloric 30 overload with high glucose dose insulin and because avoiding hypoglycaemia such high dose treatment would be too clinical demanding. Moreover, Ferrando,-

A-A; et al. (Ann-Surg. 1999 Jan; 229(1): 11-8) in an attempt to reverse the net muscle catabolism associated with severe burns, demonstrated that if large quantities of exogenous glucose required to maintain euglycemia, and hypoglycaemia in patients with severe burns promoted skeletal muscle glucose uptake and net protein synthesis but was associated with caloric overload, suggesting an hidden hypoglycaemia.

This demonstrates that intensive insulin treatment of critical ill patients for safety and efficacy of insulin and nutrient infusion therapy not only requires an intensive monitoring of blood glucose concentrations with easy and rapid access to blood glucose data and that a clear prediction per patient of the biological response to a given concentration of insulin can optimize the intensive insulin therapy of critical ill patients or subjects with insulin resistance or increased glucose uptake.

Present invention allows now to predict insulin requirement to maintain normoglycemia in an intensive care patient and to predict the impact of insulin dose versus blood glucose level on the observed outcome benefits.

Present inventions now reveals predictive factors that determine insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus glucose level on the observed outcome of benefit. Date of this invention the administration of insulin in intensive care patients can now be controlled by a titration protocol, the general guidelines for this protocol are given in the titration algorithm of this application. However, this protocol is still labor intensive.

However a second embodiment of present invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity. This automated insulin monitoring systems for intensive insulin therapy in patients in

the ICU significantly reduces the workload and human resource management problems and improves patient survivability.

5 This system can advise the medical team about the desired insulin administration rate or can apply a more automatic control. It has the following properties:

1. In the initial phase (first 24 h) the hyperglycemia is reduced, as quickly as possible, to stable normoglycemia without causing hypoglycemia.
2. The control system is robust (i.e., the blood glucose level is as stable as possible) against complicating factors (e.g., concomitant infection) and changing  
10 circumstances (e.g., decreasing insulin resistance, other route of feeding, change in medication, ...).

#### SUMMARY OF THE PRESENT INVENTION

15 Present findings clearly demonstrate that strict maintenance of normoglycemia with intensive insulin therapy reduces intensive care and hospital mortality and morbidity of critically ill adult patients in a surgical ICU. The findings of present invention reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome  
20 benefits have been established.

By a prospective, randomized, controlled trial in a single center in a 56-bed predominantly surgical ICU in a tertiary teaching hospital 1548 patients were randomly assigned to either strict normalization of blood glucose (80-110 mg/dl)  
25 with intensive insulin therapy from ICU admission onward or the conventional approach, in which insulin infusion is only initiated when blood glucose exceeds 215 mg/dL, to maintain blood glucose levels between 180 and 200 mg/dl. It was feasible and safe to achieve and maintain blood glucose levels below 110 mg/dL by using an insulin titration algorithm which takes on-admission patient- and disease-  
30 related factors such as Body Mass Index (BMI), history of diabetes, reason for ICU



admission, severity of illness, on-admission hyperglycemia, as well as the caloric intake, time in ICU and concomitant medication (glucocorticoids) into account.

Stepwise regression analysis indicated that, except for severity of illness and use of glucocorticoids, all these factors were independent determinants of mean insulin requirements, together explaining 36% of its variation.

Nutritional intake was progressively increased from a mean 550 Cal on day 1 to a mean 1600 Cal from day 7 onward. The dose of insulin required to reach normoglycemia was highest and most variable during the first 6 hours after admission (a mean of 7 units per hour; 10% of the patients required more than 20 units per hour). Normoglycemia was reached within 24h with, for a 70 kg patient, a mean 77 units per day on the first day and 94 units per day on day 7. Between day 7 and 12, caloric intake remained stable but insulin requirements decreased by 40%. Brief and clinically harmless hypoglycemia occurred in 5.2% of intensive insulin treated patients on the median 6th (IQR 2nd -14th) day versus in 0.8% of the conventionally treated patients on the 11th (2nd - 10th ) day.

The observed benefits of intensive insulin therapy on morbidity and mortality were equally present whether or not patients received enteral feeding. The lowered blood glucose level rather than the insulin dose was related to the observed reduction in mortality ( $P<0.0001$ ), critical illness polyneuropathy ( $P<0.0001$ ), bacteremia ( $P=0.02$ ) and inflammation ( $P=0.0006$ ) but not to the prevention of acute renal failure, for which the insulin dose was an independent determinant ( $P=0.03$ ). Among long-stay patients, maintaining strict normoglycemia appeared important for optimal risk reduction as intermediate (110-150 mg/dl) blood glucose levels were associated with a significantly higher incidence of most intensive care complications and death.

This study clearly demonstrates that normoglycemia can safely reached within 24h and maintained during intensive care by using simple insulin titration guidelines.

Metabolic control, as reflected by glycemia below 110 mg/dl, rather than the infused insulin dose was related to the observed protective effects of intensive insulin therapy on morbidity and mortality.

- 5 A second embodiment of present invention involves a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity.
- 10 This automated insulin monitoring systems for intensive insulin therapy in patients in the ICU significantly reduces the workload and human resource management problems and improves patient survivability.

This system can advise the medical team about the desired insulin administration rate or can apply a more automatic control. It has the following properties:

- 15 1. In the initial phase (first 24 h) the hyperglycemia is reduced, as quickly as possible, to stable normoglycemia without causing hypoglycemia.
2. The control system is robust (i.e., the blood glucose level is as stable as possible) against complicating factors (e.g., concomitant infection) and changing
- 20 circumstances (e.g., decreasing insulin resistance, other route of feeding, change in medication, ...).

#### DEFINITIONS

25

The term "systemic inflammatory response syndrome (SIRS)", as used herein refers to the uncontrolled disease process which ensues an initial insult and which gives rise to a multi system disturbance secondary to inflammatory mediators released during shock.

30

The term "sepsis", as used herein refers to "SIRS", as described above, which is particularly caused by an infectious insult leading to the initial shock phase.

5 The term "mediators of sepsis", as used herein refers to factors released by inflammatory cells, such as TNFs, interleukins, bradykinins etc.

The term "insulin receptor type tyrosine kinase", as used herein refers to a post-receptor signal transduction pathway involved in the insulin signaling.

10 The term "endoneural edema", as used herein refers to swelling of the neuronal cells.

The term "phrenic nerves", as used herein refers to the left and right nervus phrenicus, innervating the diaphragm.

15

The term "blood glucose regulator", as used herein refers to any compound which is able to regulate the blood glucose level. Examples of blood glucose regulators are insulin, active insulin derivatives, insulin analogues, glucagon like peptide 1 or its functional derivatives, compounds that stimulate signal transduction mediated by an insulin receptor type tyrosine kinase in a cell, certain protein-tyrosine phosphatases (PTP's), other type II antidiabetica, and other biologically active substances having insulin releasing action.

20

The term "Glucagon like peptide 1 (GLP-1)" as used herein is a incretin hormone.

25 This is processed from proglucagon in the gut and enhances nutrient-induced insuline release (Krcymann B., et al. , Lancet 2: 1300 – 1303 (1987)). Various truncated forms of GLP-1, particularly GLP-1 (7 – 36) amide and GLP-1 (7-37) acid, are known to stimulate insuline secretion (Mojsov S. Int. J. Peptide Protein Research 40: 333-343 (1992)); Nauck M. A., et al. Diabetologia 36: 741-744 (1993);

30 Nauck M. A., et al. J. Clin. Invest. 91: 301 – 307 (1993); Gutniak, M. et al., New England J. of Medicine 326 (20): 1316 – 1322 (1992) and Thorens B., et al.

Diabetes 42: 1219 – 1225 (1993)). Various compounds are known to stimulate secretion of endogenous GLP-I. For example, exposure of STC- 1 cells to certain secretagogues, such as, the adenylate cyclase activator, forskolin, or the protein kinase-C-stimulating agent, 12-O-tetradecanoylphobol-13-acetate (TPA), caused  
5 significant increases in release of GLP-1 (Abello Jr. et al., Endocrinol. 134: 2011 – 2017a (1994)). The STC- 1 cell line originated from an intestinal tumor in transgenic mice carrying insulin-promoting oncogenes, and STC-1 cells are known to contain mRNA transcripts of pro-glucagon, from which GLP-1 is generated. Other compounds, such as, somatostatin, gastric inhibitor polypeptide, glucose-dependent  
10 insulinotropic peptide, bombesin, calcitonin gene-related peptide, gastrin-releasing peptide, cholinergic agonists, the P-adrenergic agonist, isoproterenol, and the muscarinic cholinergic agonist, bethanechol, are similarly known to cause release of endogenous GLP-1 (Plaisancie et al., Endocrinol. 135: 2348 – 2403 (1994)), Orskov et al., Endocrinol. 119 : 1467 – 1475 (1986), Brubaker, P.L. Endocrinol. 128: 3175 –  
15 03182 (1991), Buchan A.M.J. et al., Gastroenterol. 93: 971 – 800 (1987).

The term "insulin", as used herein refers to insulin from any species such as porcine insulin, bovine insulin, and human insulin and salts thereof such as zinc salts, and protamin salts.

20

The term "active derivatives of insulin", as used herein are what a skilled art worker generally considers derivatives, vide general textbooks, for example, insulin having a substituent not present in the parent insulin molecule.

25 The term "insulin analogues", as used herein refers to insulin wherein one or more of the amino acid residues have been exchanged with another amino acid residue and/or from which one or more amino acid residue has been deleted and/or from which one or more amino acid residue has been added with the proviso that said insulin analogue has a sufficient insulin activity. Using results from the so-  
30 called free fat cell assay, any skilled art worker, for example, a physician, knows when and which dosages to administer of the insulin analogue. Examples of insulin

analogues are described in the following patents and equivalents thereto: US 5,618,913, EP 254,516, EP 280,534, US1 5 5,750,497, and US 6,011,007. Examples of specific insulin analogues are insulin aspart (i.e., AspB<sup>128</sup> human insulin), insulin lispro (i.e., LyS<sup>B28</sup>, Pro<sup>B29</sup> human insulin), and insulin glargin (i.e., Gly<sup>A21</sup> Arg<sup>B31</sup>, Arg<sup>B32</sup> human insulin). Also compounds which can be considered being both an insulin derivative and an insulin analogue can be used to practice the present invention. Examples of such compounds are described in the following patents and equivalents thereto: US 51750,497 and US 6,011,007. An example of a specific insulin analogues and derivatives is insulin detenir (i.e., des-Thr<sup>B30</sup> human insulin y LyS<sup>B29</sup> tetradecanoyl).

The term "non-diabetic patient", as used herein refers to a patient who has not been diagnosed as having diabetes.

In its broadest sense, the term a "critically ill patient" (herein designated CIP), as used herein refers to a patient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury, a patient who is being operated and where complications supervene, and a patient who has been operated in a vital organ within the last week or has been subject to major surgery within the last week. In a more restricted sense, the term a "critically ill patient", as used herein refers to a patient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury, or a patient who is being operated and where complications supervene. In an even more restricted sense, the term a "critically ill patient", as used herein refers to a patient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury.

A critically ill patient can be a patient who needs vital organ support (either mechanically such as with mechanical ventilation or dialysis etc. or pharmacologically such as with inotropes or vasopressors) without which they would not survive.

Similarly, these definitions apply to similar expressions such as "critical illness in a patient" and a "patient is critically ill".

- 5 The term "Hyperglycaemia" means a greater than normal concentration of glucose in the blood.

The term "normoglycemia" as used herein means a blood glucose between 60 and  
10 130 mg/dl, more preferably between 70 and 120 mg/dl and most preferably between 80 and 110 mg/dl.

The term "insulin resistance" as used herein, refers to a subnormal biological  
15 response to a given concentration of insulin. Insulin resistance is generally characterised by the requirement of inappropriately high levels of insulin for maintaining glucose homeostasis.

"Increased glucose turnover" is an disproportionate increase in glucose turnover  
20 Injury increases whole-body glucose turnover and whole-body glucose recycling (%). The increased glucose turnover may be seen as a way of optimising host defenses and ensuring wound repair by providing essential fuel for inflammatory and reparative tissue.

25 The terms "monomeric human insulin analog" "monomeric insulin analog" and "human insulin analog" are well-known in the art, and refer generally to fast-acting analogs of human insulin, which include human insulin, wherein Pro at position B28 is substituted with Asp, Lys, Leu, Val, or Ala, and wherein position B29 is Lys or is  
30 substituted with Pro; AlaB26-human insulin des(B28-B30) human insulin; and des(B27) human insulin. Such monomeric insulin analogs are disclosed in Chance,

et al., U.S. patent No. 5,514,646, issued May 7, 1996; Chance, et al., U.S. Patent Application Serial No. 08/255,297; Brems, et al., Protein Engineering, 6:527-533 (1992); Brange, et al., EPO publication No. 214,826 (published March 18, 1987); and Brange, et al., Current Opinion in Structural Biology 1:934-940 (1991). The  
5 monomeric insulin analogs employed in the present formulations are properly crosslinked. A properly cross-linked insulin analog contains three disulfide bridges: one between position 7 of the A-chain and position 7 of the B-chain, a second between position 20 of the A-chain and position 19 of the B-chain, and a third between positions 6 and 11 of the A-chain.

10

The term "insulin regulating" as used herein, refers to an ability to control the release of insulin into the circulation, in relation to blood glucose and fatty acid  
15 levels.

The term "pharmaceutically acceptable carrier or adjuvant" as used herein, refers to a non-toxic carrier or adjuvant that may be administered to a patient together with a compound of the invention, and which does not destroy the pharmacological activity  
20 thereof.

The terms "therapeutically or pharmaceutically effective" or "therapeutically or pharmaceutically effective amount" refers to an amount of the compound of this invention required to improve the clinical symptoms.

25

The term "Intensive Care Unit" (herein designated ICU), as used herein refers to the part of a hospital where critically ill patients are treated. Of course, this might vary from country to country and even from hospital to hospital and said part of the hospital may not necessary, officially, bear the name "Intensive Care Unit" or a  
30 translation or derivation thereof. Of course, the term "Intensive Care Unit" also

covers a nursing home a clinic, for example, a private clinic, or the like if the same or similar activities are performed there

## 5 DETAILED DESCRIPTION OF THE PRESENT INVENTION

One embodiment of present invention allows to reduce mortality in critically ill patients (who require intensive care) or the time they stay in the ICU through a software-assisted control of glycemia (concentration of glucose in the blood).

10

The regulation of blood glucose levels is a complex system controlled by several mechanisms. The secretion of insulin by the beta cells of the pancreas is one of the most important naturally occurring mechanisms in the control of glycemia. In normal circumstances, the pancreas will react to an elevated glycemia (e.g., after a meal –  
15 post-prandial secretion of insulin) by a raise of its insulin secretion, increasing the amount of this hormone in the bloodstream. This increase in insulin concentrations, in its turn, stimulates the consumption of glucose in the target tissues. This limits the elevation of the blood glucose levels which, after an initial increase, will again reach their fasting levels.

20

This (natural) control system can be disturbed by an absolute or relative shortage of insulin (causing hyperglycemia or an increased glycemia). In these cases Diabetes Mellitus can be present. In type I diabetes there is an absolute shortage of insulin caused by an immune-mediated destruction of the beta cells. In type II diabetes  
25 there is a relative shortage of insulin caused by a lower insulin sensitivity in the target tissues (also called insulin resistance – occurring in somewhat older, obese persons but also during stress – see further) and by abnormal insulin secretion.

Administration of insulin will, in many cases, be the main therapeutic intervention. It  
30 was however generally known that insulin resistance and associated hyperglycemia are common in critically ill patients requiring intensive care (including mechanical



ventilation) mostly after major surgery (even if they did not have diabetes before). In the past, this was ignored because it was believed that hyperglycemia was a beneficial reaction to stress (Van den Berghe G et al. N Engl J Med 2001; 345: 1359-1367).

5

However, recently it was showed that normalization of glycemia (between 80 and 110 mg/dl = normoglycemia), through a rigorous administration of insulin, resulted in a spectacular reduction in mortality (e.g., the number of deaths in patients who required intensive care for more than five days was reduced from 20.2% to 10.6%..

10 For the moment, the administration of insulin in intensive care patients is controlled by a labor intensive (considerable workload for the nurses) and empirical protocol (in which a certain degree of freedom is still given – human experience plays an important role). The protocol now requires that blood glucose levels are measured every four hours (or more frequently, especially in the initial phase or after  
15 complications). The flow of the continuous insulin infusion is then adjusted using a certain schedule ('Intensive insulin therapy in the critically ill')

A titration algorithms has now been developed by present invention with determinants of insulin requirements and impact of insulin dose versus glycemic  
20 control on outcome benefits.

This protocol for obtaining and maintaining normoglycemia, preferably a glycemia below 110 mg/dl and above 80 mg/dl, takes into account the following complicating factors:

- 25 - Caloric intake (number of calories, class (proportion of carbohydrates, proteins and fat) and daily interruption of caloric intake) which have been found to have a profound impact on the insulin requirements.
- Switch from intravenous glucose infusion to total parenteral feeding (also intravenously given) and finally to enteral feeding which can profoundly change the  
30 dynamics of the process (here the patients are presented as an abstract process with inputs (e.g., administration of insulin) and outputs (e.g., glycemia)).

- the substantial difference between the purpose of the initial phase and the stable or complication phase. In the initial phase, the aim is to obtain normoglycemia as soon as possible. In the stable or complication phase the aim is to maintain blood glucose levels preferably between 80 and 110 mg/dl and to take care that acute events (like infections) have minimal impact (prevention of deviation from normoglycemia).
- Administration of drugs (e.g., glucocorticoids) which was found to be a disturbing factor on the blood glucose levels.
- The constitution or profile of the patient which was found to influence the reaction on insulin administration.

Another embodiment of present invention is a control system that adapts the flow of the insulin infusion using the measurements of the blood glucose levels. This system can (continuously or discontinuously) advise the medical team (physicians or nurses) about the desired insulin administration rate or can, after further validation, apply a more automatic control fig. 5).

Preferably this control system has the following properties:

1. In the initial phase, hyperglycemia is reduced, as quickly as possible, to stable normoglycemia without causing hypoglycemia.
  2. It is robust (i.e., the blood glucose level must be as stable as possible) against complicating factors (some of these factors can possibly be regarded as inputs of the process, like the caloric intake or the administration of glucose)
- The actual implementation of this control system for clinical use is a considerably reduction of the efforts necessary to optimize glycemia.

The control system of present invention can be used for patients in the critical care unit, in the coronary care unit, medical intensive care units or during and after surgical or obstetric procedures. This control system can comprise computer-assisted insulin administration, eventually through a subcutaneous insulin pump

Date of the present invention it is clear that the control system of present that adapts the flow of the insulin infusion can be even used for patients in less critical wards but subjected to insulin resistance and/or increased overall insulin turnover  
5 for instance for a subject with obesity disorder. An embodiment of present invention can thus be a computer-assisted insulin administration, eventually through a continuous subcutaneous insulin pump, in a subject confronted with a requirement of inappropriately high levels of insulin for maintaining glucose homeostasis and disproportionate increase in glucose turnover due to a condition of stress or multi-  
10 factorial diseases through a continuous subcutaneous insulin pump for control of blood glucose levels at home.

In one embodiment of present control system the blood glucose levels are sampled manually. In second embodiment the blood glucose levels are measured by  
15 electrochemical sensors, with sampling times in the order of magnitude of minutes for electrochemical sensors instead of hours as for blood sample measurements.

The model of present invention predicts blood glucose levels given the insulin administration rate and potential disturbances. The model approximates the  
20 dynamic behavior of the process for instance the significant time delays can occur between the administration of insulin and its effect on glycemia and the hard constraints on inputs and outputs which are possible, for instance a maximum rate of insulin administration.

25

Preferably this model has different functions depending on the control structure choice, and its complexity depends on its necessary accuracy.

## DESCRIPTION OF THE ILLUSTRATIVE EMBODIMENT

30

### Example 1

## Material and Methods:

STUDY POPULATION & STUDY DESIGN

5

The study population (mechanically ventilated adults admitted to our predominantly surgical ICU over a one year episode), has been described in detail elsewhere (Van den Berghe G, et al. N Engl J Med. 2001; 345: 1359-1367). Informed consent had been obtained from the closest family member upon ICU admission. The study  
10 protocol was approved by the Institutional Ethical Review Board.

A study design has been used as described in detail in Van den Berghe G, et al. N Engl J Med. 2001; 345: 1359-1367, Van den Berghe G, et al N Engl J Med. 2001; 346). At intensive care admission, all patients were started on partial nutritional  
15 support with intravenous glucose (200 to 300 g/24h) and from the next day onward with a standardised feeding schedule with the intention to administer 20 to 30 non-protein Calories/kg/24h with a balanced composition (0.13 to 0.26 g nitrogen/kg/24h and 20 to 40 percent of non-protein Calories as lipids) (Ortiz A, et al. J Invest Med. 1997; 45: 50-56) of total parenteral, combined parenteral/enteral or full enteral  
20 feeding (Table 1). Enteral feeding was attempted as early as possible, at the discretion of the attending physician.

Upon ICU admission, patients were randomly assigned to either intensive or conventional insulin treatment. Assignment to treatment groups was done by blinded envelopes, stratified according to type of critical illness [(1) cardiac surgery,  
25 (2) neurological disease, isolated cerebral trauma or brain surgery, (3) thoracic surgery and/or respiratory insufficiency, (4) abdominal surgery and/or peritonitis, (5) vascular surgery, (6) multiple trauma and severe burns, (7) transplantation, and (8) others] and balanced with the use of permuted blocks of ten.

30 Adjustment of the insulin dose was based on measurement of whole blood glucose in undiluted arterial blood every one- to four-hours with the use of a glucose

analyzer (ABL700, Radiometer Medical A/S, Copenhagen – the coefficient of variation was 2.84 % at 90 mg/dl and 3.57 % at 220 mg/dl). The dose was adjusted according to a titration algorithm, as stipulated below, by the intensive care nurses, supervised by a study physician who was not involved in the clinical care of the patients.

## INSULIN TITRATION

### *General aspects*

10

It was advised to consider the titration algorithms as directives that required integration of the guidelines with several patient- and disease-specific aspects such as obesity; pre-existing type I or type II diabetes; type and severity of critical illness; caloric intake, concomitant or intercurrent infections or other complications, the concomitant administration of drugs affecting insulin sensitivity such as glucocorticoids.

15

### *Insulin infusion*

- Insulin was given exclusively by continuous intravenous infusion through a central venous line using a 50 mL syringe driven pump (Perfusor-FM® pump; B. Braun, Melsungen, Germany). The standard concentration was 50 IU Actrapid HM® (Novo Nordisk Denmark) in 50 ml NaCl-0.9%.
- Prepared solutions, stable for up to 24h when kept below 25°C, were not to be used beyond that time.

25

### *Measurement of blood glucose levels*

- Whole blood glucose levels were measured in undiluted arterial blood. Undiluted samples were obtained by removing at least 4 times the flush-volume in the arterial line between the sampling point and the arterial puncture site before the actual sample was taken.

30

- During the first 12 to 24h after admission to ICU, until the targeted range of blood glucose level was reached, one- to two-hourly measurement of blood glucose was advised. Thereafter, blood glucose was measured every 4 hours, unless steep falls or rises in blood glucose level occurred, for which hourly control after each dose adjustment was advised.

*Special concerns regarding alterations in caloric intake*

- Attention was drawn to always assure adequate administration of the prescribed nutrients.
- In order to avoid fluctuating blood glucose levels and too frequent need for re-adjustment of the insulin dose, IV glucose-containing solutions were always administered by infusion pump.
- At the time of planned interruptions of feeding, the insulin dose was reduced proportionately in order to avoid hypoglycemia. Hence, in a patient on total enteral nutrition, insulin was virtually stopped during the twice daily 2h interruptions of tube feeding. In some patients, however, including those who were suffering from diabetes and requiring insulin before ICU admission, a low maintenance dose was needed during that time.
- At the time of patient transportation to an investigation or to the operating room for surgery, all IV and enteral administration of feeding was usually stopped and insulin infusion was temporarily discontinued. Blood glucose level was measured to ensure an adequate level before transport.
- Whenever a patient was extubated and assumed to re-start (limited) oral food intake, the IV or tube feeding was usually reduced in order to allow appetite to re-occur. The insulin dose was proportionately reduced, often temporarily discontinued.

*Special concerns about concomitant drugs*

- When glucocorticoids were given in high doses (> 90 mg /d hydrocortisone or its equivalent), insulin dose was increased to overcome the associated insulin resistance. The total daily dose of glucocorticoids was administered as a

continuous infusion to avoid fluctuating insulin requirements occurring with intermittent bolus injections.

5 *Special concerns in a patient at risk for acute renal failure in whom an hourly substitution of urinary fluid loss was applied to avoid fluctuating intravascular filling status.*

- In order to co-adjust insulin dose with the variable amounts of glucose containing solutions (glucose 5%, glucose 3.3% or glucose 2.5%) infused to substitute the variable hourly urine output , 16, 12 or 10 IU insulin per liter of  
10 substitution fluid, respectively, were added to the infusion bag. This insulin administration was additional to the hourly dose, which was given separately by infusion pump.

#### INSULINE THERAPY AND STUDY OBJECTIVES

##### 15 Intensive Insulin Therapy:

##### *Starting of insulin infusion and initial stabilisation of blood glucose level*

- When blood glucose level exceeded 110 mg/dl (6.1 mmol/l), insulin was started at 2 IU/h (4 IU/h if first blood glucose level exceeded 220 mg/dl).
- 20 • When next blood glucose was > 140 mg/dl, insulin dose was increased by 2 IU/h.
- When next blood glucose level was 110-140 mg/dl, insulin was increased by 1 IU/h.
- When blood glucose approached 80-110 mg/dl, insulin was adjusted by 0.1 –  
25 0.5 IU/h.
- When blood glucose level was 80-110 mg/dl, insulin dose was unaltered.

##### *Dose adjustments after initial stabilisation*

- Dose adjustments were *proportionate* to the observed change in blood  
30 glucose. When blood glucose decreased by >50%, dose was reduced to half and blood glucose level checked within the next hour.

- When blood glucose was 60-80 mg/dl, insulin was reduced depending on the previous blood glucose level and blood glucose level checked within the next hour.
- When blood glucose was 40-60 mg/dl, insulin infusion was stopped, adequate baseline glucose intake was assured and blood glucose level checked within the next hour.
- When blood glucose was <40 mg/dl, insulin infusion was stopped, adequate baseline glucose intake was assured, glucose was administered per 10 g IV boluses and blood glucose level checked within the next hour.
- When blood glucose started to decrease within the normal range in a stable patient, recovery of insulin sensitivity was assumed and insulin dose reduced by 20%.
- Additional blood glucose controls were advised when changes in body temperature and/or infection occurred.
- At discharge from ICU, a less strict approach was adopted (glycemia  $\leq 200$  mg/dL) in order to avoid hypoglycemia in the less well controlled setting of a regular ward. When a (previously non-insulin requiring) patient was normoglycemic on < 2 IU /h insulin, the insulin infusion was stopped. Blood glucose level before discharge was targeted below 200 mg/dL. When insulin was required to maintain blood glucose level below 200 mg/dL, the patient was presumed to have pre-existing diabetes and follow up by an endocrinologist was planned.

#### Conventional Insulin Therapy

25

##### *Starting up and dose adjustment of insulin infusion*

- As soon as blood glucose level exceeded 215 mg/dL (12 mmol/L), insulin infusion was initiated at a starting dose of 1 IU/h.
- When a control blood glucose level was > 200 mg/dL, insulin dose was increased by increments of 1 IU/h



- Once blood glucose level was between 180 and 200 mg/dl, insulin dose was kept constant
- When blood glucose level decreased below 180 mg/dL, insulin infusion was decreased until blood glucose level was between 180-200 mg/dl. Insulin dose was further decreased and eventually completely stopped when blood glucose levels decreased further. Insulin infusion was only re-started when blood glucose exceeded 215 mg/dl.

### Study objectives

10

The primary clinical results of this study, which involved 1548 patients (783 treated conventionally and 765 treated with intensive insulin therapy), were published previously (Van den Berghe G, et al; N Engl J Med. 2001; 345: 1359-1367).

The aims of the current analysis were:

- 15 (1) to report on feasibility and safety of intensive insulin therapy in the ICU by providing details of feeding strategy, insulin requirements and blood glucose control over time
- (2) to statistically define the factors that independently determine insulin requirements
- 20 (3) to analyse the separate impact of glycemic control and amount of exogenous insulin infused on mortality and morbidity outcome measures (development of critical illness polyneuropathy as diagnosed by blinded weekly systematic EMG screenings, acute renal failure requiring dialysis, bacteremia, prolonged inflammatory responses as defined by C-reactive protein (CRP)-level > 150 mg/l for more than 3 days) and transfusion requirements.
- 25 (4) to study the impact on outcome measures of strict normoglycemia (< 110 mg/dl) compared with an intermediate level of blood glucose control (110-150 mg/dl) among long-stay patients.

### STATISTICAL ANALYSIS

Data are presented as means $\pm$ SEM or medians (25<sup>th</sup> to 75<sup>th</sup> percentile) unless indicated otherwise.

Difference between study groups were analysed by Chi-square test, unpaired  
5 Student's t-test, Mann Whitney-U test and Mantel-Cox log-rank test, when appropriate. Multivariate logistic regression analysis was performed to assess the impact of blood glucose level versus insulin dose on the observed outcome benefits. After univariate simple regression analysis, stepwise forward and backward regression analysis was done to define the independent determinants of  
10 the insulin dose required to maintain normoglycemia. P-values below 0.05 were construed significant.

### **EXAMPLE 2 Results**

15 Detailed description of daily caloric intake, insulin doses and blood glucose control over time in conventionally treated patients and in patients receiving intensive insulin therapy

Daily caloric intake, insulin requirements and blood glucose levels (including the  
20 upon admission blood glucose level and the highest blood glucose level reached during the first 24h in ICU) are depicted in Fig. 1.

All patients underwent a gradual transition from intravenous glucose infusion upon ICU admission to normocaloric balanced nutrition comprising glucose, proteins and  
25 lipids, preferably administered via the enteral route. Hence, daily caloric intake progressively increased until ICU day 7, equally in both study groups, starting from a mean 8 Cal/kg/day and reaching a mean 24 Cal/kg/day (Fig. 1, first panel). This strategy resulted in comparable amounts of calories, glucose, proteins and lipids in both study groups at all times, a prerequisite for attributing observations to intensive  
30 insulin therapy.

Of all patients in ICU for >5 days (N=451), the group among whom intensive insulin therapy reduced mortality, 60% (N=267) received combined parenteral-enteral feeding with up to a mean 68% of nutrients administered enterally. After 7 days ICU, 85% of the patients received at least partial enteral nutrition. Intensive insulin  
5 therapy was equally effective whether or not patients received enteral feeding in ICU: mortality was reduced from 18.8% to 10.2% ( $P<0.05$ ) in the group in ICU for >5 days and receiving combined parenteral-enteral feeding, and from 22.3% to 11.1% ( $P<0.05$ ) in the parenterally fed only group. Effects on morbidity were equally independent of feeding regimen.

10

With the nutritional strategy applied, 99% of patients in the intensive insulin group required exogenous insulin to maintain mean blood glucose levels at (mean  $\pm$  SEM)  $103\pm1$  mg/dl. In the conventionally treated group, only 39% of patients revealed blood glucose levels peaking over 215 mg/dl and thus required exogenous insulin.  
15 Mean blood glucose level for the entire conventionally treated group therefore was  $153\pm1$  mg/dl and  $173\pm2$  mg/dl for the subgroup requiring insulin. In both study groups, targeted ranges of blood glucose were reached within 24h of intensive care.

Mean $\pm$ SEM insulin dose per day was  $68\pm2$  units in the patients randomized to  
20 receive intensive insulin therapy ( $70\pm2$  units per day in the patients actually receiving insulin) and  $12\pm1$  units per day in the conventionally treated patients ( $41\pm3$  units per day in the patients actually receiving insulin). The mean hourly doses on a daily basis are depicted in Fig. 1, second panel. Insulin requirements in order to reach normoglycemia were highest and most variable during the first 6 hours after  
25 admission (mean 7 units per hour, in 10% of the patients more than 20 units per hour). Normoglycemia was reached within 24h with, for a 70 kg patient, a mean 77 units per day for a mean 550 Calories on the first day and 94 units per day on ICU day 7 when full nutrition was given (a mean 1600 Calories). After day 7, caloric intake remained constant though insulin doses decreased by 40% from day 7 to day  
30 12, remaining stable thereafter. At all times, the within-patient variability of the

insulin dose remained within a mean 75% (95% confidence interval of 25% to 125%) of the insulin dose on day 1.

In 0.8% of conventionally treated patients and 5.2% of intensive insulin treated patients ( $P < 0.0001$ ), hypoglycemia ( $< 40$  md/dl) occurred after a median 11 (IQR 2 – 20) and 6 (2-14) days, respectively ( $P = 0.6$ ). In 18% of the intensive insulin treated patients who encountered hypoglycemia, such an event occurred at more than one [median 3 (IQR 2-4)] occasion. More than one hypoglycemic event did not occur in conventionally treated patients. Of all episodes of hypoglycemia, 90% occurred after stable blood glucose levels within the targeted range had been reached and 62% of those occurred in association with interruption of enteral feeding, which was inadvertently done without adequately reducing the insulin dose. Because of the frequent insulin dose adjustments, particularly when blood glucose levels dropped steeply, hypoglycemia episodes were always brief and serious complications, such as hemodynamic deteriorations, convulsions or permanent consequences, did not occur.

#### Factors determining insulin requirements

On univariate analysis, the factors significantly correlated with hourly insulin dose required to maintain normoglycemia were BMI ( $R = 0.34$ ), history of diabetes ( $Rho = 0.50$ ), reason for ICU admission ( $Rho = 0.08$ ), APACHE-II on admission ( $Rho = 0.10$ ), blood glucose level on admission ( $R = 0.34$ ), mean daily caloric intake ( $R = 0.23$ ), concomitant treatment with glucocorticoids ( $Rho = 0.37$ ), and time in ICU ( $R = -0.14$ ) (Fig. 1 and Fig. 2). Stepwise regression analysis revealed that they were all independent determinants, except for APACHE-II score (Souba WW. Et al. N Engl J Med. 1997; 336:41-48) (positively correlated with on-admission glycemia;  $Rho = 0.14$ ;  $P < 0.0001$ ) and concomitant treatment with glucocorticoids (related to reason for ICU admission: more than 86% of the transplanted patients received glucocorticoids versus 24-30% among all other patient groups;  $P < 0.0001$ ). Taken together, the independent factors (in order of impact : history of diabetes, BMI,

blood glucose level on admission, caloric intake, time in ICU and reason for ICU admission) explained 36% of the variability in mean hourly insulin requirements to maintain normoglycemia.

5 Caloric intake, an independent determinant of insulin dose required to maintain normoglycemia, varied according to the type of illness (more calories were given to vascular surgery patients, brain surgery or cerebral trauma patients and multiple trauma patients compared with other subgroups) and with time in ICU (Fig. 1, first panel). Hence, assessment of differences in insulin requirement to maintain the  
10 preset glycemic range with time in ICU (Fig. 1, third panel) and among the different patient groups (Fig. 2) was done by comparing the ratio of hourly insulin dose (IU/h) over caloric intake (Cal / kg BW / 24h). In the intensive insulin treated patients, in whom blood glucose levels were tightly "clamped" between 80-110 mg/dL and hence virtually similar at all times, this ratio of insulin dose over caloric intake is also  
15 a surrogate marker of insulin resistance. In both study groups, this ratio continued to decrease significantly over time ( $P < 0.0001$ ) (Fig. 1, third panel).

Among patients in ICU for more than 5 days, the route of feeding determined this ratio : the insulin dose required to maintain normoglycemia, corrected for caloric intake per kg body weight, was a median 26% higher in exclusively parenterally fed  
20 patients compared with those receiving at least some enteral nutrition ( $P = 0.007$ ).

Analysis of the impact of actual glycemic control versus mean amount of infused insulin on mortality and morbidity (Table 1, 2 and Figs 3, 4).

25

For the entire study group, the mean daily insulin dose and the mean blood glucose level were entered into a multivariate logistic regression model together with all other univariate determinants of adverse outcome (age, delayed ICU admission, on-admission APACHE-II score, reason for ICU admission, history of malignancy and  
30 diabetes, on-admission hyperglycemia) (McCowen KK et al. Crit. Care Clin 2001; 17: 107 – 124; O' Niel D.A. et al Stroke 1991, 22: 842-847; Capes SE, et al.

Lancet 2000; 355: 773-778). For *ICU mortality* (Table 1), both the mean daily amount of infused insulin ( $P=0.005$ ) and the mean level of blood glucose during ICU stay ( $P<0.0001$ ) were independent *positive* risk factors. For *critical illness polyneuropathy* ( $P<0.0001$ ), *bacteremia* ( $P=0.02$ ) and *need for red cell transfusion* ( $P=0.06$ ) (Table 2), only the mean level of blood glucose during ICU stay, and not the insulin dose, appeared to be an independent risk factor. For the occurrence of *prolonged inflammation* (defined as more than 3 days CRP level above 150 mg/l), the insulin dose ( $P=0.02$ ) and the level of blood glucose ( $P=0.0006$ ) were independent positive risk factors. In contrast, for *acute renal failure and the need for renal replacement therapy*, not the actual level of blood glucose but the dose of insulin was an independent negative predictor ( $P=0.03$ ).

Among the long-stay patients (ICU stay > 5 days), the group among which intensive insulin therapy reduced mortality and morbidity, there was a gradual decrease in risk of ICU (Fig 3) and hospital death (Fig. 4) with decreasing blood glucose levels (<110 mg/dl; 110-150 mg/dl; >150 mg/dl) without an identifiable threshold below which no further risk reduction occurred. Also for the occurrence of *critical illness polyneuropathy*, *bacteremia*, *need for red cell transfusion* and *acute renal failure*, the risk was lower among patients with maintained strict normoglycemia compared with patients in whom the blood glucose level was moderately elevated (110-150 mg/dl). There was no identifiable threshold blood glucose level below which no further reduction of risk of these complications occurred (Fig. 3). In contrast, for prevention of prolonged inflammation, as defined by a CRP-level of > 150 mg/l for > 3 days, the threshold blood glucose level may be higher than 110 mg/dl (Fig. 3).

## Discussion

Strict maintenance of normoglycemia with intensive insulin therapy has shown to reduce intensive care and hospital mortality and morbidity of critically ill adult patients in a surgical ICU (Van den Berghe G, et al. N Engl J Med. 2001; 345: 1359-1367). We here report that lowering of blood glucose, achieved with insulin

titration according to a simple algorithm, rather than the actual amount of insulin given was most significantly related to the observed reduction in mortality, critical illness polyneuropathy, bacteremia, inflammation and anemia but not to the prevention of acute renal failure, for which the insulin dose was an independent  
5 determinant.

Normoglycemia could be effectively and safely reached within 24h after ICU admission and maintained throughout ICU stay by medically-supervised, nurse-controlled insulin titration, guided by a simple titration algorithm. A few on-  
10 admission patient- and disease-related factors (BMI, history of diabetes, reason for ICU admission, on-admission hyperglycemia) (McCowen KC, et al. Crit Care Clin. 2001; 17: 107-124, O'Neill PA, et al. Stroke. 1991; 22: 842-847, Knaus WA, et al. Crit Care Med. 1985; 13:818-829; Capes S.E. et al. Lancet 2000; 355: 773 – 778), the mean daily amount of calories per kg body weight, the time in ICU and  
15 concomitant medication such as glucocorticoids, were able to predict insulin requirements for 36%. This indicates that 64% of the insulin dose adjustments were not predictable by the studied variables and thus were based on the frequently measured blood glucose levels and empirically guided by factors such as the time course of the previous changes in blood glucose level, an eventual rise in body  
20 temperature and intercurrent infections, as advised in the insulin titration guidelines. Episodes of hypoglycemia occurred infrequently, although more often with intensive insulin therapy than with conventional insulin therapy. Hypoglycemic episodes were never accompanied by serious adverse events because the algorithm guaranteed quick detection and correction. Hypoglycemia occurred in the stable phase and  
25 was mostly attributable to human error such as inadequate insulin dose reduction during interruption of enteral feeding. After implementation of intensive insulin therapy as part of routine clinical patient care in our ICU, these errors appeared avoidable with progressively increasing experience of the nursing team. Targeting the blood glucose control so strictly below 110 mg/dl appeared necessary to  
30 optimally prevent ICU and in-hospital deaths, critical illness polyneuropathy, bacteremia, anemia and acute renal failure, as even moderate hyperglycemia (110-

150 mg/dl) was associated with higher risk of these complications. Hence the higher risk of brief hypoglycemia was clearly outweighed by the observed benefits of intensive insulin therapy.

5 In the studied population who received progressively increasing amounts of nutritional support, from a mean 550 Cal to a mean 1600 Cal over the first 7 days of intensive care administered via the parenteral and/or enteral route, the lowering of blood glucose rather than the amount of infused insulin which was related to the observed benefits of the intervention, as indicated by the multivariate logistic regression analysis. Although the study was not specifically designed to evaluate  
10 the separate impact of infused insulin and of metabolic control, these results point to an important role of the latter. Indeed, although direct effects of insulin such as anti-inflammatory effects through suppression of cytokine production or signalling (Dandona P. J. Clin. Endocrinol. Metabl. 2001, 86: 3257 – 3265) or anabolic effects (Ferrando AA, et al. Ann Surg 1999; 229: 11-18) may have played a role, favorable  
15 effects mediated specifically by the prevention of hyperglycemia appear to have dominated. Examples of the latter are improvement of coagulation and fibrinolysis (Carr ME. J Diabetes Complications 2001; 15: 44-54) and of macrophage function (Kwoun MO, et al. J Parent Enteral Nutr. 1997; 21: 91-95), acting alone or together. Whether the lowering of the blood glucose was the primary effector or rather a  
20 simple reflection of other metabolic effects of intensive insulin therapy, such as improved clearance and hence less toxicity of circulating fatty acids, remains unclear.

The results also indicate that the observed benefits of our strategy to maintain normoglycemia with insulin (average 0.04 IU/kg/h) during normal intake of glucose  
25 (9 g/h) and calories (mean 19 Cal/kg/day) probably differ from those of "glucose-insulin-potassium" (GIK) solutions, used for improvement of cardiac performance during and after myocardial injury (Svensson S, et al. J Thorac Cardiovasc Surg. 1990; 99: 1063-1073; Fath-Ordoubadi F, et al; Circulation 1997; 96: 1152-1156, 23). The goal of GIK infusions is to stimulate myocardial metabolism of glucose  
30 instead of fatty acids when oxygen supply is compromised. Hence, GIK solutions include a much higher dose of both insulin (ranging from 0.1 to 1 IU/kg/h depending



on the protocol used) and glucose (ranging from 30 to 80 g/h) than what we provided, and, most importantly, these solutions are infused *without* targeting normoglycemia. In fact, most studies on GIK have reported substantial hyperglycemia. We found that it was a low level of blood glucose, rather than a

5 high insulin dose, which apparently protected against most ICU complications and death, without an identifiable threshold, below which no further risk reduction occurred. For prevention of prolonged inflammatory responses, defined as CRP levels higher than 150 mg/l for more than 3 days, during critical illness, however, blood glucose levels somewhat higher than 110 mg/dl may still be effective.

10 The prevention of acute renal failure, for which the insulin dose was an independent determinant, appeared a notable exception. This observation may either point to a direct protective effect of insulin on the kidney or to the fact that insulin is to a large extent cleared through the kidney (Rabkin R, et al. N Engl J Med. 1970; 282: 182 – 187), which may reduce the need for exogenous insulin in patients with acute renal

15 failure. Alternatively, the lower insulin requirements to maintain normoglycemia in patients on hemofiltration can also be explained by the fact that hemofiltration clears glucose from the blood proportionately to the hemofiltration volume and thus to a much greater extent than does the normal kidney.

20 Insulin requirements, particularly when corrected for body weight and caloric intake, decreased steadily with time in ICU. Insulin doses needed to obtain normoglycemia were highest and varied substantially among patients during the first 6 hours after ICU admission. Within the first 24 hours, normoglycemia was reached with on average, for a 70 kg patient, 70 units of insulin per 500 Calories. Maintenance of

25 normoglycemia was achieved with insulin doses progressively decreasing to about 20 units per 500 Calories on day 7 of intensive care. Besides this progressively decreasing insulin requirement, within-patient insulin dose variations remained limited. Since the majority (87%) of the patients were not previously diabetic, and since blood glucose levels in the intensive insulin group were indeed adequately

30 clamped around 100 mg/dl from day 1 until the last day in ICU, the decreasing

insulin requirements with time in ICU reflect several fold improvement of either insulin resistance and/or endogenous insulin production.

We observed a 26% higher insulin requirement to maintain normoglycemia for identical amounts of calories in patients who received exclusively parenteral feeding compared with those who received enteral nutrition. This can be explained by the incretin effects on insulin secretion with enteral feeding in non-diabetic subjects (Kieffer TJ, Habener JF. *Endocr Rev.* 1999; 20: 876-913) . Furthermore, endogenous insulin released by enteral feeding is likely to induce more pronounced suppression of hepatic gluconeogenesis and more hepatic glucose uptake than peripherally infused insulin (Zucker GJ, et al. *Diabetes.* 1997; 46: 372-378).

The higher insulin requirements to obtain normoglycemia in patients fed with parenteral compared with enteral feeding indicates that parenterally fed patients are more at risk for hyperglycemia. Furthermore, the outcome benefits of intensive insulin therapy were present regardless of the feeding regimen. Hence, our observations have implications for the controversy on early enteral feeding (Braga M, et al. *Crit Care Med.* 1998; 26: 24-30; Zaloga GP. et al. *Crit Care Med.* 1999; 27: 259-261). Indeed, some of the reported benefits of early enteral feeding may be explained by the concomitant lower risk of hyperglycemia. Our data suggest that the outcome advantage of early enteral nutrition as compared with parenteral feeding may fade when intensive insulin therapy is given to avoid hyperglycemia.

Normoglycemia was thus safely reached within 24h and maintained during intensive care by using simple insulin titration guidelines. The lowering of blood glucose levels, or effects reflected by normoglycemia, rather than the amount of infused insulin per se was related to the observed protective effects of intensive insulin therapy on morbidity and mortality.

### Example 3

30

In present invention a system has been developed that can advise the medical team about the desired insulin administration rate or can apply a more automatic control. It has the following properties:

1. In the initial phase (first 24 h) the hyperglycemia is reduced, as quickly as possible, to stable normoglycemia without causing hypoglycemia.
2. The control system is robust (i.e., the blood glucose level is as stable as possible) against complicating factors (e.g., concomitant infection) and changing circumstances (e.g., decreasing insulin resistance, other route of feeding, change in medication, ...).

10

A general overview of the control system can be inspected in Figure 5. The system consists of three main parts:

1. Sensor: the glycemia is measured by a glucose sensor that uses blood obtained through or present in an arterial line (which is present in most patients in the ICU).
2. The actuator: consists of a programmable insulin pump, which delivers insulin by continuous intravenous infusion through a central venous line. The pump can be programmed manually, based on the insulin dose proposed by the controller. In this configuration the system acts purely as an advising system, whose advice can still be overruled. The programming can also be performed automatically by the controller, using a serial link or an IR link, depending on the specific hospital situation.
3. The control system: this system adapts the insulin infusion levels to the measured glycemia and incorporates two main components (see Figure 6):
  - a. The mathematical (adaptive) model of the patient: in the initial phase an initial model is used based on the 'profile' or 'constitution' of the patient (factors that can influence the basal or mean insulin requirements; this profile can consist of the following variables:

30

BMI, prior history of diabetes, reason for ICU admission) and on-admission parameters (APACHE-II on admission, on-admission glycemia, caloric intake on admission, concomitant glucocorticoids on admission). According to this profile and the on-admission parameters, patients are classified into distinct classes each associated with their own parameter settings for the initial model. After the initial phase, the incoming closed-loop measurements are used to adapt the initial parameters of the model such that it more closely approximates the dynamic behaviour of the glycemia in that particular patient. Moreover, in this phase the model parameters can also be tuned by input data that can influence the dynamic behaviour of the patient (evolution of caloric intake + route of administration + composition, evolution of medication (e.g., glucocorticoids) + dose, time elapsed since admission on the ICU, evolution of severity of disease score). In this way the uncertainty on the parameter estimates can be reduced to improve the controller performance.

A low-order ARX-model is used as patient model :

$$x_{k+1} = c_1 x_k + c_2 x_{k-1} + \dots + c_n x_{k-n+1} + c_{n+1} u_k + c_{n+2} u_{k-1} + \dots + c_{2n} u_{k-n+1}$$

where  $x_k$  is the *state* of the patient at discrete time k (in this case the blood glucose level),  $u_k$  is the *input* of the patient model at discrete time k (in this case the insulin infusion flow) and  $c_i$  are parameters determining the model behaviour. Due to the complex behaviour of ICU-patients and wide variation in patient conditions it is impossible to determine a unique set of parameters  $c_i$  describing all possible patients. Therefore, using the patient profile and on-admission parameters, patients are classified into different groups

and for each group an optimal set of parameters  $c_i$  is determined in function of the above stated factors. This is done by analysing prior patients glucose level and insulin infusion flow measurements and extracting each patients model parameters  $c_i$ . Using classical statistical techniques it is then possible to calculate the expected values of the  $c_i$  and the expected estimation error  $\Delta c_i$  for each class given the profile of the patient and the on-admission parameters.

This way the obtained model more closely resembles the real patients expected behaviour. Similarly, the estimation error  $\Delta c_i$  will be smaller compared to the case when none of the above mentioned factors are used. In the controller the estimation error is used to achieve robustness against model uncertainty and thus this reduction of the estimation error  $\Delta c_i$  is aimed to keep the control problem feasible and improve its performance.

Alternatively, instead of an ARX-model, a state-space model can also be used to achieve similar results, but this has the drawback that the number of parameters is potentially larger, complicating the statistical analysis.

In another alternative setting, physical understanding of glucose dynamics in the human body can be incorporated in the model to decrease the number of free parameters.

During operation of the controller, the model parameters  $c_i$  are updated to represent the dynamics of the patients glucose level. This can e.g. be done in a Bayesian statistical framework, using the initial guess of the parameters as *prior knowledge* and the measured closed-loop data as *new observations*. Alternatively, other algorithms (e.g. RLS) for adaptive filtering can be applied.

- b. The controller: A choice can be made between the use of a PID- or an MPC-controller. The latter increases performance but also increases computational demand on the controller hardware, leading to an increased cost. In both cases the adaptive patient model (see above), along with the calculated uncertainty on the parameter estimates, is used in the control scheme to obtain a robust controller.

In case of a PID-controller (state feedback controller with proportional, integrating and differential component)

$$u = K \left( x + \frac{1}{T_i} \int x dt + T_d \frac{dx}{dt} \right),$$

the controller parameters  $K, T_i, T_d$  are recalculated using the current patient model parameters  $c_i$ . Since the patient is a stable SISO (Single-Input Single-Output) system, this can be done using the classical Ziegler-Nichols method, where  $K, T_i$  and  $T_d$  are calculated using the following rules

$$K = \frac{1.2}{RL}$$

$$T_i = 2L$$

$$T_d = \frac{L}{2}$$

where  $R$  and  $L$  are parameters determined by the step response of the system. These can thus be calculated directly from the  $c_i$  e.g. by online simulation.

Robustness against model uncertainty can be achieved by using the estimated  $\Delta c_i$  to calculate the patients worst case response instead of the most likely response.

5 After updating the  $K, T_i, T_d$ , the controller can be applied directly to calculate the recommended insulin infusion flow. Other existing rules of thumb for the choice of  $K, T_i, T_d$  can also readily be used instead of the above suggested Ziegler-Nichols method.

10 In case of an MPC-controller the model is explicitly used to formulate the optimization problem that is solved in each time step to obtain the recommended insulin infusion flow

$$\min_{x,u} \left( \sum_{i=1}^P x_{k+i}^T Q x_{k+i} + \sum_{i=0}^{P-1} u_{k+i}^T R u_{k+i} \right)$$

subject to

15

$$x_{k+1} = c_1 x_k + \dots + c_n x_{k-n+1} + c_{n+1} u_k + \dots c_{2n} u_{k-n+1} \quad k = 1 \dots p$$

where  $Q$ ,  $R$  and  $P$  are fixed design parameters of the controller. In this way the control action is automatically adjusted to the adaptive model of the patient.

20

In each case (PID/MPC), the calculated control action (insulin infusion flow) is recalculated on a regular basis. This sampling time can range from 15min. to up to 2hrs., depending on the type of controller selected and the type of interface to the actuator (manual or automatic). This to accommodate the specific hospital situation and demands as good as possible.

25

**Example 4**

One way to control processes, such as dosing of insulin to intensive care patients, in a more optimal way is by applying model based control theory. Such control strategies require (1) continuous feedback of the process output to control  
 5 and (2) the availability of a process model that predicts the dynamic response of the process output to the control input. For implementation in practice, such model should be compact and accurate. An overview of this approach applied to an efficient automated control of insulin to intensive care patients is shown in Fig. 7.

10

The (r)evolution in modern hardware techniques (price, computational power, reliability, compact dimensions) and software makes it possible today to use advanced mathematical techniques for modeling complex processes on-line. These modeling techniques estimate the model parameters of a mathematical  
 15 model structure based on dynamic measurements of the process inputs and outputs. The estimation of the model parameters can be performed on-line during the process resulting in a dynamic model with time-variant model parameters that can cope with the dynamic, time-variant behavior of most bioprocesses. An example of the performance (in terms of mean relative prediction error MRPE) of  
 20 such compact on-line model as a function of prediction horizon and time window (number of measurements used to estimate the model parameters at each time instant) is shown in Figure 8.

In order to model the static and dynamic responses discrete transfer function  
 25 models can be used, which have the following general model structure (in the single-input, single-output case:

$$y(k) = \frac{B(z^{-1})}{A(z^{-1})} u(k) + \xi(k) \quad (1)$$

30 with



$y(k)$  = output at time  $k$ ,

$u(k)$  = input at time  $k$ ,

$\xi(k)$  = additive noise, assumed to be a zero mean, serially uncorrelated sequence

- 5 of random variables with variance  $\sigma^2$  accounting for measurement noise, modeling errors and effects of unmeasured inputs to the process,

$$A(z^{-1}) = 1 + a_1.z^{-1} + a_2.z^{-2} + \dots + a_{na}.z^{-na},$$

$$B(z^{-1}) = b_0 + b_1.z^{-1} + b_2.z^{-2} + \dots + b_{nb}.z^{-nb},$$

$a_j, b_j$  = model parameters to be estimated,

- 10  $z^{-1}$  = backward shift operator,  $z^{-1}.y(t) = y(t-1)$ ,

$na, nb$  = orders of the respective polynomials,

- The parameters of a transfer function (TF) model may be estimated using various methods of identification and estimation. Although Least Squares (LS) is one of
- 15 the most commonly used model estimation algorithms, the estimated model parameters become asymptotically biased away from their true values in the presence of measurement or disturbance noise (Young, 1984). To avoid this bias, an instrumental variable approach can be applied. This technique makes use of prefiltered input and output variables (i.e. instrumental variables) to
- 20 estimate the model parameters. Under normal conditions, the algorithm converges after three iterations resulting in parameter estimates which are asymptotically unbiased, consistent and efficient in statistical terms. The technique presented for single-input single output systems with time-invariant parameters, can also be used for multiple-input multiple-output systems and
- 25 systems with time-variant parameters.

In order to obtain the control law, model predictive control (MPC) makes use of an objective function  $J$ . The general aim is that the future process output ( $y$ ) on the considered horizon should follow a determined reference signal ( $r$ ) and, at the

same time, the control effort ( $\Delta u$ ) necessary for doing so should be penalized. The general expression for such objective function is:

$$J(N_1, N_2, N_u) = \sum_{F=N_1}^{N_2} \delta(F) [\hat{y}(t+F|t) - r(t+F)]^2 + \sum_{F=1}^{N_u} \lambda(F) [\Delta u(t+F-1)]^2$$

5

where  $N_1$  is the minimum cost horizon;  $N_2$  is the maximum cost horizon;  $N_u$  is the control horizon,  $\hat{y}(t+F|t)$  is the predicted value of the process output  $y$  (i.e. blood glucose level) on time instant  $t$ ,  $F$  time steps ahead;  $r(t+F)$  is the value of the reference trajectory (i.e. desired blood glucose level) on time instant  $t+F$ ;  
 10  $\Delta u(t+F-1)$  is the change of the control input (i.e. insulin dose) on time instant  $t+F-1$ ;  $\delta(j)$ ,  $\lambda(j)$  are weighing coefficients.

#### Glucose sensors

15 Different types of sensors (e.g., optical sensors) for frequent, fast, real time, continuous blood-glucose measurement and/or non invasive measuring glucose levels are available.

Optical measurement of glucose can, for instance, be performed by focusing a  
 20 beam of light onto the body. Optical sensors can determine the glucose concentration by analyzing optical signal changes in wavelength, polarization or intensity of light. Various methods are available for accurate of the sensor measurements. One method (e.g., multivariate spectral analysis) utilizes calibration models developed by initially measuring known glucose  
 25 concentrations to correct subsequent sensor measurements. The calibration models become inaccurate over time due to dynamic changes in physiological processes. Another method (e.g., adaptive noise canceling) utilizes signal processing to cancel portions of the sensor measurements unrelated to glucose concentration. For example, two substantially simultaneous sensor

measurements at different wavelengths can be used to make up a composite signal which can be processed to cancel its unknown and erratic portions.

Several optical methods can be used for the continuous monitoring of glucose, but the two that show the most promise are. Fully implantable devices, measure glucose in whole blood and involve implanting a light source and detector and sending the result out of the body via a radio-frequency signal. Optochemical devices, which measure glucose via the skin's interstitial fluid and involve implanting a chemical sensor just under the skin and stimulating it with external light.

One approach of optical glucose sensing is based on the fact that glucose solutions have a magnetic optical rotatory effect such that when a magnetic field is set up in a glucose solution there is a rotation of the polarization vector of the incident light that is proportional to the path length, magnetic field strength, and the concentration of glucose in the solution.

For example, U.S. Pat. No. 5,036,861 (issued to Sembrowich et al. on Aug. 6, 1991) describes a wrist-mountable device having an electrode which measures glucose present in sweat at the skin surface.

U.S. Pat. No. 5,222,496 (issued to Clarke et al. on Jun. 29, 1993) describes an infrared glucose sensor mountable, for instance, on a wrist or finger.

U.S. Pat. No. 5,433,197 (issued to Stark on Jul. 18, 1995) describes determination of blood glucose through illuminating a patient's eye with near-infrared radiation.

U.S. Pat. Nos. 5,115,133, 5,146,091 and 5,197,951 (issued to Knudson on May 19, 1992, Sep. 8, 1992 and Jan. 19, 1993, respectively) describe measuring blood glucose within blood vessels of a tympanic membrane in a human ear through light absorption measurements.

US patent US6517482, Nov. 1, 2000, Elden H.R. et al teaches a method and apparatus for non-invasive determination of glucose in body fluids

European Patent Publication No.0 351 891 B 1, to Hill et al., teaches a method of making an electrochemical sensor by printing. The sensor is used to detect, measure or monitor a given dissolved substrate in a mixture of dissolved substrates, most specifically glucose in body fluid.

5 U.S. Patent No.5,391,250, to Cheney et al., teaches a method of fabricating thin film electrochemical sensors for use in measuring subcutaneous or transdermal glucose. Fabrication of the sensors comprises placing a thin film base layer of insulating material onto a rigid substrate. Conductor elements for the sensors are formed on the base layer using contact mask photolithography  
10 and a thin film cover layer.

U.S. Patent No. 5,437,999, to Diebold et al., teaches a method of fabricating thin film electrochemical devices which are suitable for biological applications using photolithography to define the electrode areas.

The disclosures of each of the above patent specifications are incorporated  
15 herein by reference in their entirety.

Different systems of implantable optical sensors are for instance available at MiniMed, BioTex, Animas, SpectRx, Dermal Therapy Inc. and Sensors for Medicine and Science Inc. Animas, for instance, developed a long-term  
20 implantable (e.g. across a vein with readings transmitted via radio waves (RF telemetry) to a small Display Unit), optical sensor suitable for continuous and accurate monitoring of blood glucose levels. This Animas sensor is based on Spectroscopy and measures the near-infrared absorption of blood and MicroSense International has developed a handheld probe that measures  
25 glucose levels without drawing blood.

#### Actuator

The actuator (automatic dosing device) can be an insulin pumps

30 By coupling the instrument according to the invention with a pump or other device which can deliver insulin, an insulin releasing factor or other therapeutic agent to

the patient, using a transmitter, or other suitable communication device, such that the pump or device is responsive to the signal input, normoglycemia monitoring may be achievable.

- 5 For example, the transmitter may remotely transmit the signal to a pump, such as a servo pump, having a receiver responsive to the transmitted signal. The pump is preferably responsive to information derived from controller.

The pump may then provide insulin or other appropriate medication to the  
10 patient. Alternately, or in addition, the information may be sent to a remote monitor.

Various infusion pump systems have been described in the current art and  
15 include U.S. Patent No. 4,704,029, to Van Heuvelen, which teaches a blood glucose monitor which is applicable for use as an implantable unit for controlling an insulin pump.

U.S. Patent No. 4,436,094, to Cerami, teaches a method for continuous monitoring of the glucose concentration which can be tied to an infusion device.

20 U.S. Patent No. 5,665,065, to Colman et al., teaches a medication infusion device with a blood glucose data input method.

U.S. Patent No. 5,383,865, to Michel, teaches a medication dispensing device comprising an injector attached to a cartridge with a drive mechanism.

U.S. Patent No. 5,176,644, to Srisathapat et al., discloses a medication infusion  
25 pump with a simplified pressure reservoir.

The disclosures of the above patents are incorporated herein by reference.

## Legends

### Figure 1

Daily caloric intake (Calories per day and kg body weight – top panel), insulin requirements [insulin dose per day expressed as mean amount of units per hour (panel 2) ; insulin dose per hour corrected for caloric intake per kg body weight (panel 3)] and mean blood glucose levels [including the upon admission blood glucose level (d0) and the highest blood glucose level reached during the first 24h in ICU (peak d1) – bottem panel] for the first 4 weeks in ICU.

Filled bars represent patients receiving intensive insulin therapy and open bars the patients receiving conventional therapy. Data represent means  $\pm$  SEM. P-values are obtained by Mann Whitney-U test at the different time points. Caloric intake was increased progressively during the first 7 days, and insulin doses corrected for caloric intake progressively decreased over time in ICU, which for the intensive insulin treated patients, in view of their virtually identical blood glucose levels, indicated a progressively improving insulin resistance and/or endogenous insulin secretion.

### Figure 2

Mean daily insulin doses (Units per hour) corrected for caloric intake per kg body weight for the different independent upon-admission determinants of outcome (hyperglycemia > 200 mg/dl at ICU admission, a history of diabetes, a high BMI and reason for ICU admission) in both study groups (intensive insulin treated patient in black bars; conventionally treated patients in open bars).

The higher insulin requirements to maintain normoglycemia in the transplantation group ( $P < 0.0001$  vs. all other groups) were explained at least partially by the concomitant administration of high doses of glucocorticoids. Data are expressed as means  $\pm$  SEM. P-values were obtained using Mann Whitney-U test or ANOVA, when appropriate. \*\*\*\*  $P < 0.0001$  and \*\*  $P = 0.005$  vs. all other groups.

### Figure 3

Percent risk of death in ICU, development of critical illness polyneuropathy, bacteremia, inflammation (CRP-level higher than 150 mg/l for more than 3 days), need for more than 2 red cell transfusions and acute renal failure requiring hemofiltration/dialysis among long-stay (>5 days) patients stratified for mean blood glucose levels. Black-filled bars represent patients with a mean blood glucose level below 110 mg/dl; gray-filled bars represent patients with a mean blood glucose level between 110 mg/dl and 150 mg/dl; open bars represent patients with a mean blood glucose level higher than 150 mg/dl. P-values were obtained using Chi-square-test. \*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*\*  $P < 0.0001$  and indicate the level of significance of the difference between the <110 mg/dl and the 110-150 mg/dl groups.

#### Figure 4

Kaplan-Meier cumulative risk of in-hospital death among long-stay (> 5 days in ICU) patients with a mean blood glucose level below 110 mg/dl (squares); with a mean blood glucose level between 110 mg/dl and 150 mg/dl (bullets) and patients with a mean blood glucose level higher than 150 mg/dl (diamonds).

P-value of 0.0009, obtained with Mantel-Cox log-rank test, indicates the significance level of the overall difference among the groups and P-value of 0.026 indicates the significance level of the difference between the <110 mg/dl and the 110-150 mg/dl groups.

#### Figure 5.

Schematic representation of the control scheme.

The patient's glycemia is measured by a glucose sensor. The controller calculates the desired insulin infusion flow of the actuator (the pump) such that the amount of administered insulin moves the blood glucose level of the patient to, or keeps it at the desired level (i.e., such that glycemia is stabilized between 80 mg/dl and 110 mg/dl). Note that the control of the insulin pump can be either direct or indirect (i.e., the final decision can still be taken by the medical team). See Figure 2 for a more detailed description of the controller.

Figure 6.

Schematic representation of the control system.

The initial patient model is calculated using the patient profile and the on-admission  
5 parameters (BMI, prior history of diabetes, reason for ICU admission, APACHE-II on  
admission, on-admission glycemia, caloric intake on admission, concomitant  
glucocorticoids on admission).

The measured glycemia ( $x_k$ ) enters the control system and is used in two ways.  
First it is used, together with the current model parameters and the control history,  
10 to update the dynamic patient model. In case of a PID-controller, the updated model  
is used to recalculate the parameters of the PID-controller. In case of an MPC-  
controller the model is directly used to formulate a patient-specific optimization  
problem. Secondly, both PID and MPC-controllers then use the measured glycemia  
to calculate the recommended insulin dose ( $u_k$ ).

15 Moreover, after the initial phase, the patient model can also be fine tuned using the  
parameters that can influence the patient dynamics (evolution of caloric intake +  
route of administration + composition, evolution of medication (e.g., glucocorticoids)  
+ dose, time elapsed since admission on the ICU, evolution of severity of disease  
score).

20

Figure 7.

Principle of an automated model-based insulin controller.

\* disturbances: BMI, history of diabetes, reason for ICU admission, severity of  
25 illness, on-admission hyperglycemia, caloric intake, time in ICU and concomitant  
medication (glucocorticoids)

Figure 8.

Performance (in terms of mean relative prediction error MRPE) of a compact on-line  
30 model as a function of prediction horizon and time window (number of



measurements used to estimate the model parameters at each time instant) for a biological growth process.

Table 1

Table 1 : multivariate regression analysis of all univariate determinants of ICU mortality

	OR	95 % CI	P - value
age (per added year)	1.036	1.014-1.058	0.001
delayed ICU admission	1.882	1.069-3.314	0.03
on-admission APACHE II > 9	5.054	2.524-10.120	<0.0001
reason for ICU admission (vs. cardiac surgery OR 1)			
multiple trauma or severe burns	4.851	1.664-14.141	0.004
neurological disease, cerebral trauma or brain surgery	4.814	2.044-11.339	0.0003
thoracic surgery and/or respiratory insufficiency	2.966	1.242-7.084	0.01
abdominal surgery and/or peritonitis	2.466	1.017-5.979	0.05
transplantation	0.746	0.197-2.820	0.7
vascular surgery	1.336	0.433-4.123	0.6
other	1.904	0.642-5.644	0.2
history of malignancy	1.504	0.779-2.905	0.2
on-admission hyperglycemia ( $\geq 200$ mg/dl)	1.128	0.601-2.116	0.7
history of diabetes	0.356	0.158-0.803	0.01
daily insulin dose (per added unit)	1.006	1.002-1.009	0.005
mean blood glucose level (per added mg/dl)	1.015 *	1.009-1.021	<0.0001

- 5   \* An odds ratio of 1.015 for mean blood glucose level indicates that for every mg/dl increase in blood glucose concentration, the risk of death increases with 15 per 1000. In other words, for a blood glucose level of 200 mg/dl, the risk of death is 2.5 times higher than for a blood glucose level of 100 mg/dl.
- 10 Identifying daily insulin dose (per added unit) as a positive rather than a negative risk factor for death in ICU indicates that it was not the amount of infused insulin per se which mediated the reduction of ICU mortality with intensive insulin therapy.

Table 2

**Table 2 : multivariate regression analysis of the impact of insulin dose versus blood glucose level on morbidity, after correction for age, reason for ICU admission, APACHE-II, history of malignancy and diabetes and for on-admission hyperglycemia**

	O R	95 % C I	P - value
<i>critical illness polyneuropathy</i>			
daily insulin dose (per added unit)	0.999	0.995-1.003	0.7
mean blood glucose level (per added mg/dl)	1.012 *	1.007-1.018	<0.0001
<i>bacteremia</i>			
daily insulin dose (per added unit)	1.000	0.996-1.004	0.9
mean blood glucose level (per added mg/dl)	1.007	1.001-1.014	0.02
<i>&gt;3 days CRP&gt;150 mg/l</i>			
daily insulin dose (per added unit)	1.004	1.001-1.007	0.02
mean blood glucose level (per added mg/dl)	1.008	1.003-1.012	0.0006
<i>acute renal failure requiring renal replacement therapy</i>			
daily insulin dose (per added unit)	0.994	0.988-1.000	0.03
mean blood glucose level (per added mg/dl)	1.001	0.994-1.007	0.9
<i>&gt; 2 red cell transfusions</i>			
daily insulin dose (per added unit)	0.998	0.994-1.002	0.3
mean blood glucose level (per added mg/dl)	1.005	1.000-1.011	0.06

- 5 \* An odds ratio of 1.012 for mean blood glucose level indicates that for every mg/dl increase in blood glucose concentration, the risk of critical illness polyneuropathy increases with 12 per 1000. In other words, for a blood glucose level of 200 mg/dl, the risk of critical illness polyneuropathy is 2.2 times higher than for a blood glucose level of 100 mg/dl.

10

## Claims

What is claimed is:

- 5 1) An apparatus configured to maintain normoglycemia in a subject under a condition of insulin resistance or under a condition of increased glucose turnover, comprising: a sensor to measure glycemia level in said subject, a programmable actuator to delivery a blood glucose regulator to said subject and a control system to adapts the administration levels of said blood glucose regulator to a desired  
10 glycemia level in said subject, the control system comprising an adaptive patient model.
- 2) An apparatus configured to maintain normoglycemia a critical ill person, comprising: a sensor to produce a signal indicative of the glycemia level in said  
15 subject, a programmable actuator adapted to delivery a blood glucose regulator to said subject and a control system adapted to regulate the administration levels of said blood glucose regulator to a normoglycemia level in said subject, the control system comprising an adaptive patient model.
- 20 3) The apparatus of any of the claims 1 to 2, wherein the adaptive patient model in the initial phase is based on factors that determine the initial patient model (patient profile + on-admission parameters) and in a later phase on factors that influence the dynamic behaviour of the patient.
- 25 4) The apparatus of any of the claims 1 to 2, wherein he control system comprises two main components: the mathematical (adaptive) model of the patient which in the initial phase an initial model is used based on the 'profile' or 'constitution' of the subject (factors that can influence the basal or mean blood glucose regulator requirements) and after the initial phase, the incoming closed-  
30 loop measurements are used to adapt the initial parameters of the model such

that it more closely approximates the dynamic behaviour of the glycemia in that particular subject.

5) The apparatus of claim 4, wherein the profile of said subject comprise one or more of the following variables: BMI, prior history of diabetes, reason for ICU admission.

6) The apparatus of claim 5, wherein the ICU admission parameters comprise one or more of the following parameters APACHE-II on admission, on-admission glycemia, caloric intake on admission, concomitant glucocorticoids on admission.

10

7) The apparatus of claim 5, wherein the on-admission parameters, patients are classified into distinct classes each associated with their own parameter settings for the initial model.

8) The apparatus of claim 4 or 5, wherein the model parameters are tunable by input data that can influence the dynamic behaviour of the subject.

9) The apparatus of claim 1 or 2, wherein the control system is applying a model based on a process model that predicts the dynamic response of the process output to the control input.

10) The apparatus of claim 1 or 2, wherein the control system comprises: a continuous feedback of the process output to control and a process model that predicts the dynamic response of the process output to the control input.

25

11) The apparatus of claim 9 or 10, wherein prefiltered input and output variables (i.e. instrumental variables) are used to estimate the model parameters.

12) The use of said apparatus of any claim 1 to 11, in treatment with a blood glucose regulator of a subject under a condition of insulin resistance or under a condition of increased glucose turnover.

30

- 13) The use of said apparatus of any claim 1 to 11, in treatment with a blood glucose regulator of a critical ill patient..
- 5 14) The use of claim 12 or 13, wherein the blood glucose regulator is insulin.
- 15) The use of claim 12 or 13, wherein the blood glucose regulator is a insuline analogue or an active derivative of insulin.
- 10 16) The use of claim 12 or 13, wherein the blood glucose regulator is a monomeric human insulin analogue.
- 17) The use of claim 12 or 13, wherein the blood glucose regulator is glucagon like peptide 1 (a GLP-1), a GLP-1 analogs, GLP-1 derivatives and pharmaceutically  
15 acceptable salts thereof.
- 18) The use of claim 12 or 13, wherein the blood glucose regulator a compound of the group consisting of somatostatin, gastric inhibitor polypeptide, glucose-dependent insulintropic peptide, bombesin, calcitonin gene-related peptide,  
20 gastrin-releasing peptide, cholinergic agonists, isoproterenol, and bethanechol.
- 19) The use of said apparatus of any claim 1 to 11, to reduce hyperglycemia to stable normoglycemia in subject under a condition of insulin resistance or under a condition of increased glucose turnover without causing hypoglycemia in an initial  
25 phase of less than 24 hours and to maintain normoglycemia under changing conditions of said subject (e.g., decreasing insulin resistance, other route of feeding, change in medication, ...) or complications of said subject (e.g., concomitant infection).
- 30 20) The use of said apparatus of any claim 1 to 11, to reduce hyperglycemia to stable normoglycemia in a critically ill subject without causing hypoglycemia in an

initial phase of less than 24 hours and to maintain normoglycemia under changing conditions of said subject (e.g., decreasing insulin resistance, other route of feeding, change in medication, ...) or complications of said subject (e.g., concomitant infection) .

5

21) The use of said apparatus of any claim 1 to 11, to maintain blood glucose below 110 mg/dl in a critical ill patient.

22) The use of said apparatus of any claim 1 to 11, to maintain blood glucose  
10 between 60 and 130 mg/dl in a critical ill patient.

23) The use of said apparatus of any claim 1 to 11, to maintain blood glucose between 70 and 120 mg/dl in a critical ill patient.

15 24) The use of said apparatus of any claim 1 to 11, to maintain blood glucose between 80 and 110 mg/dl in a critical ill patient.

25) The use of said apparatus of any claim 1 to 11, to reach normoglycemia in critical ill patient within 24h after admission in the ICU (initial phase) and to  
20 maintain normoglycemia.

26) The use of said apparatus of any claim 1 to 11, on a critical ill patient to prevent or decrease the incidence of blood stream infection, to reduce morbidity and mortality in the critical care, to prevent or decrease the incidence of  
25 prolonged inflammation, to prevent or decrease the incidence of acute renal failure, to prevent or decrease the incidence of polyneuropathy, to prevent or decrease the incidence of immune-mediated destruction of the beta cells, to prevent or decrease the incidence of systemic inflammatory response syndrom (SIRS) to prevent or decrease the incidence of sepsis, to prevent or decrease the  
30 incidence of endoneural edema, to prevent or decrease the incidence of phrenic nerves or to decrease dialysis or hemofiltration.

Figure 1






Figure 2




Figure 3




Figure 4




Fig. 5






Figure 6




**Figure 7.**

Principle of an automated model-based insulin controller.

\* disturbances: BMI, history of diabetes, reason for ICU admission, severity of illness, on-admission hyperglycemia, caloric intake, time in ICU and concomitant medication (glucocorticoids)

## BEST AVAILABLE COPY

Figure 8



## INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/BE 03/00050

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61M5/142 A61M5/172

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 83007 A (ASPECT MEDICAL SYSTEMS INC) 8 November 2001 (2001-11-08) page 7, line 10 -page 9, line 30 page 12, line 15-18 page 16, line 20 -page 17, line 3 page 18, line 27-29 page 20, line 12-17 page 31, line 26-30 ---	1,3-6, 8-11
X	US 6 017 318 A (GAUTHIER ROBERT T ET AL) 25 January 2000 (2000-01-25) column 2, line 1-36 column 10, line 57 -column 11, line 11 column 14, line 33-57 column 26, line 54 -column 27, line 23 --- -/--	1,3-6, 8-11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

31 July 2003

Date of mailing of the international search report

19/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Krassow, H



## INTERNATIONAL SEARCH REPORT

Internationa Application No  
PCT/BE 03/00050

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 806 738 A (SOC ET TECH S E T) 12 November 1997 (1997-11-12) the whole document ----	1, 3-6, 8-10
X	US 4 280 494 A (COSGROVE JR ROBERT J ET AL) 28 July 1981 (1981-07-28) column 2, line 58 -column 5, line 59 column 11, line 9 -column 12, line 42 -----	1, 4, 6, 8-11

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 2,7

Although independent claims 1 and 2 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter, i.e. overlap in scope, and to differ from each other only with regard to the definition of the subject-matter for which protection is sought or in respect of the terminology used for the features of that subject-matter.

Drafting two independent claims which overlap in scope results in a lack of clarity as it is not possible to unambiguously determine which subject-matter should represent the invention for which protection is sought. The claims as a whole fail to comply with the requirements of clarity and conciseness (Article 6 and Rule 6.1(a) PCT).

Therefore, a search has only been carried out for the parts of the application which seem to represent the invention for which protection is sought, i.e. claims 1 and its dependent claims, and no search has been carried out for claim 2.

Furthermore, claim 7 is unclear (Article 6 PCT) in a way that no meaningful search was possible. Due to the wording of the claim, it is unclear whether the claim is intended to be directed to the definition of "the on-admission parameters" or "the classification of the patients". In any case, however, the exact meaning was not understood.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/BE 03/00050

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12-26  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: 2,7  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT  
nation on patent family members

Internationale Application No  
PCT/BE 03/00050

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0183007	A	08-11-2001	AU 5938001 A	12-11-2001
			BR 0110515 A	08-04-2003
			CA 2409366 A1	08-11-2001
			EP 1278564 A2	29-01-2003
			WO 0183007 A2	08-11-2001
			US 2003036744 A1	20-02-2003
			US 2003045858 A1	06-03-2003
US 6017318	A	25-01-2000	US 5697899 A	16-12-1997
			AU 4967596 A	04-09-1996
			CA 2212414 A1	22-08-1996
			EP 0831946 A2	01-04-1998
			JP 11500029 T	06-01-1999
			NO 973630 A	07-10-1997
			WO 9625186 A2	22-08-1996
EP 0806738	A	12-11-1997	FR 2748588 A1	14-11-1997
			EP 0806738 A1	12-11-1997
US 4280494	A	28-07-1981	US 4533346 A	06-08-1985